91ÊÓƵ

Pain medication management is the process of evaluating, prescribing, monitoring, and adjusting medications used to treat pain. It includes reviewing the diagnosis, pain type, current medications, prior medication response, side effects, risks, drug interactions, and treatment goals. At MPM, medication management is not treated as a refill service or a one-size-fits-all approach. It is part of diagnosis-first pain care and may include non-opioid options, nerve pain medications, migraine medications, anti-inflammatory strategies, autoimmune medication coordination, or controlled-substance oversight when appropriate.

MPM considers the pain diagnosis, pain mechanism, medical history, medication history, side effects, current prescriptions, allergies, imaging, labs when relevant, and functional goals. Different pain types may respond to different medication classes. Nerve pain, inflammatory pain, migraine, pelvic pain, fibromyalgia, CRPS, autoimmune-related pain, and spine-related pain may require different strategies. MPM also considers safety factors such as liver or kidney function, cardiac risks, pregnancy considerations, mental health history, sedation risk, constipation, and medication interactions.

Non-opioid options may include acetaminophen, anti-inflammatory medications, neuropathic pain agents, certain antidepressant-class medications used for pain, antiepileptic-class medications used for nerve pain, topical medications, muscle-related medications, migraine medications, or disease-directed medications when appropriate. The right option depends on the diagnosis and safety profile. Non-opioid does not automatically mean risk-free. MPM reviews dosing, interactions, liver or kidney concerns, blood pressure, stomach risks, sedation, mood effects, and other safety considerations before recommending a plan.

Nerve pain medications may include certain antiepileptic-class medications, antidepressant-class medications, topical treatments, local anesthetic strategies, or other options depending on the diagnosis. These may be considered for burning, tingling, electric, radiating, or hypersensitive pain patterns, including peripheral neuropathy, small fiber neuropathy, trigeminal neuralgia, CRPS, or nerve-related pelvic pain. MPM evaluates the likely nerve pain source, prior medication response, side effects, sedation risk, interactions, and whether additional testing or specialist coordination is needed.

Medication management may help selected patients with fibromyalgia or central pain syndromes, but medication alone is rarely the full answer. These conditions may involve heightened pain sensitivity, sleep disruption, fatigue, mood changes, stress physiology, and functional limitations. MPM may consider medications that support pain modulation, sleep, or symptom burden when appropriate. Treatment may also include pain psychology, biofeedback, movement-based care, pacing, infusions, or evaluation for overlapping conditions. Medication decisions are individualized and monitored for benefit and side effects.

Yes, medication management can be an important part of chronic migraine and headache care. Depending on the diagnosis, the plan may include acute medications, preventive medications, medication-overuse review, nausea management, trigger planning, or coordination with procedures such as botulinum toxin or nerve blocks. MPM first classifies the headache pattern because chronic migraine, cluster headache, tension headache, hemicrania, trigeminal autonomic cephalalgias, and secondary headaches require different strategies. Sudden or changing headache symptoms may require urgent evaluation.

Medication management may support selected pelvic pain patients, especially when symptoms involve nerve pain, pelvic floor spasm, inflammatory pain, centralized pain, endometriosis-related pain overlap, pudendal neuralgia, pelvic dystonia, or PGAD-related distress. Medication does not replace pelvic specialty care, pelvic floor therapy, gynecology, urology, nerve evaluation, or procedures when those are needed. MPM evaluates the pelvic pain pattern and considers medication as one part of a coordinated care plan.

Medication management may support autoimmune-related pain, but autoimmune and inflammatory conditions often require coordinated care with rheumatology or other specialists. Patients with rheumatoid arthritis, lupus, Sjogren’s, vasculitis, undifferentiated connective tissue disease, psoriasis, or seronegative spondyloarthropathy may need anti-inflammatory strategies, DMARDs, biologics, lab monitoring, infection screening, and disease-specific care. MPM helps connect pain management with the broader diagnosis and avoids treating autoimmune pain as simple musculoskeletal pain.

DMARDs, or disease-modifying antirheumatic drugs, and biologics are medications used to treat certain autoimmune or inflammatory diseases by reducing disease activity or targeting parts of the immune system. They are not general pain medications and may require rheumatology coordination, lab monitoring, infection screening, medication review, and careful follow-up. MPM may consider these treatments within the broader care plan when autoimmune or inflammatory disease is relevant, but they are not prescribed automatically and must be matched to the diagnosis.

Opioids may be considered only in selected situations after careful evaluation of diagnosis, risks, benefits, prior treatments, function, safety, and alternatives. They are not first-line for many chronic pain conditions and are not appropriate for every patient. If opioid therapy is considered, MPM may use controlled-substance safeguards such as prescription monitoring, medication agreements, urine drug testing, side effect review, sedation risk review, constipation management, overdose risk education, and reassessment of whether the medication is improving function and safety.

Buprenorphine is a medication that may be used in different clinical contexts, including opioid use disorder treatment and selected pain care situations. Suboxone is one formulation that contains buprenorphine and naloxone. It is not automatically appropriate for pain and requires individualized clinical judgment. MPM evaluates diagnosis, opioid history, safety, medication interactions, treatment goals, and monitoring needs before considering buprenorphine or Suboxone pain management NYC care. Coordination with other clinicians may be needed.

Medication safety may include medication reconciliation, side effect review, interaction checks, liver or kidney review, blood pressure monitoring, pregnancy considerations, mental health screening, sedation risk review, constipation management, infection screening for immunosuppressive medications, lab monitoring, and coordination with other clinicians. For controlled substances, monitoring may also include prescription monitoring, controlled-substance agreements, urine drug testing, dose review, and reassessment of risks and benefits. The goal is to reduce harm while supporting the patient’s broader pain care plan.

If a medication is not working, MPM evaluates whether the diagnosis is correct, whether the medication matches the pain type, whether the dose or duration was adequate, whether side effects limited use, and whether another treatment pathway is needed. Lack of response can suggest that the pain generator has not been fully identified or that medication alone is not enough. MPM may recommend medication changes, further evaluation, imaging, labs, procedures, infusions, pain psychology, biofeedback, rehabilitation, or specialist coordination.

Yes. Medication management is often combined with other treatments when clinically appropriate. Depending on the diagnosis, this may include ultrasound-guided injections, spine procedures, infusions, ketamine therapy, lidocaine and ketamine infusions, pain psychology, biofeedback, acupuncture, physical therapy, pelvic floor therapy, headache care, rheumatology care, neurology care, or surgical evaluation. MPM uses medication as one component of coordinated pain care, not as the only treatment when the condition requires a broader plan.